=>
=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:57:50 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 DEC 2006 HIGHEST RN 914612-67-2
DICTIONARY FILE UPDATES: 3 DEC 2006 HIGHEST RN 914612-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10529431generic.str





ring nodes :
1 2 3 4 5 6 7 8 9 10
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10
exact/norm bonds :
1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 09:58:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4703 TO ITERATE

42.5% PROCESSED 2000 ITERATIONS 46 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 89948 TO 98172
PROJECTED ANSWERS: 1539 TO 2787

L2 46 SEA SSS SAM L1

=> d l1 scan
L1 HAS NO ANSWERS

=> d l2 scan

L2 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 1H-[1,4]Diazepino[1,2-a]benzimidazole, 2,3,4,5-tetrahydro-1-methyl-, (S)-(9CI)
MF C12 H15 N3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 8b,10a-Diaza-2a,4a-diazoniacyclopenta[cd]fluoranthene, 3,4,9,10-tetrahydro-, dibromide (9CI)
MF C14 H14 N4 . 2 Br



●2 Br⁻

L2 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Imidazo[1,2-a]pyrazin-2(3H)-imine, 5,6,7,8-tetrahydro-7-(phenylmethyl)-
(9CI)
MF C13 H16 N4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 8H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine,
9-[(4-chlorophenoxy)acetyl]-9,10,11,12-tetrahydro- (9CI)
MF C22 H20 Cl N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 46 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 8H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-carboxamide,
6-amino-11,12-dihydro-N,N-dimethyl- (9CI)
MF C17 H20 N6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> s l1 sss full
FULL SEARCH INITIATED 09:58:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    94403 TO ITERATE

100.0% PROCESSED    94403 ITERATIONS                          2181 ANSWERS
SEARCH TIME: 00.00.01

L3         2181 SEA SSS FUL L1

=> s danorubicin/cn
L4            0 DANORUBICIN/CN

=> exp danorubicin/cn
E1            1     DANOMYCIN A, MONOACETATE (SALT)/CN
E2            1     DANOMYCIN B/CN
E3            0 --> DANORUBICIN/CN
E4            1     DANOSTEINE/CN
E5            1     DANOVAOL/CN
E6            1     DANOX 35ST/CN
E7            1     DANOX LF 102/CN
E8            1     DANOX R 3204/CN
E9            1     DANOXAMINE/CN
E10           1     DANPHENONE 110A/CN
E11           1     DANPHENONE BEP 1000/CN
E12           1     DANPHENONE BEP 1000, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZ
                    ENE, DT 300, FD 190/CN

=> s doxorubicin/cn
L5            1 DOXORUBICIN/CN

=> s epirubicin/cn
L6            1 EPIRUBICIN/CN

=> s idarubicin/cn
L7            1 IDARUBICIN/CN

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           186.86     187.07

FILE 'CAPLUS' ENTERED AT 09:59:47 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

FILE COVERS 1907 - 4 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 3 Dec 2006 (20061203/ED)


```
=> s l3/thu
           175 L3
        835303 THU/RL
L8          13 L3/THU
                (L3 (L) THU/RL)

=> d L5-L7
'L5-L7' IS NOT A VALID ACCESSION NUMBER

The number entered is not a valid accession number in this file.
Enter "HELP ACCESSION" at an arrow prompt (=>) for a list of valid
accession number formats in the current file.

=> s L5-L7
         16798 L5
          2427 L6
          1475 L7
L9       18780 (L5 OR L6 OR L7)

=> s L8 and L9
L10          0 L8 AND L9

=> s L8 and anthracycline
          5723 ANTHRACYCLINE
L11          0 L8 AND ANTHRACYCLINE

=> s l3 and (L5-L7 or anthracycline)
           175 L3
         16798 L5
          2427 L6
          1475 L7
          5723 ANTHRACYCLINE
L12          0 L3 AND ((L5 OR L6 OR L7) OR ANTHRACYCLINE)

=> s l8 and (cancer or carcinoma or neoplas? or tumor)
        298785 CANCER
        152207 CARCINOMA
        472329 NEOPLAS?
        390780 TUMOR
L13          5 L8 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)

=> d l13 1-5 ti abs bib
```

L13 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds as immunomodulators and their preparation, pharmaceutical compositions and use in treatment of viral and neoplastic diseases

GI



I



II

AB Substituted fused [1,2]imidazo[4,5-c] ring compds. of formula I (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines), pharmaceutical compns. containing the compds., intermediates, methods of making the compds., and methods of use of these compds. as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. Compds. of formula I wherein X is a bond, or (un)substituted (un)branched C1-8 alkylene; X' is (un)substituted (un)branched C1-8 alkylene; X and X' are further characterized in that the sum of the ring carbons contributed by X and X' is 1,2 or 3; Z is O or substituted amine; RA and RB are independently H, halo, alkyl, alkenyl, alkoxy, alkylthio or NH2 and derivs.; R1 is (un)substituted alkylene, (un)substituted alkenylene, etc.; and their pharmaceutically acceptable salts. Example compound II was prepared by silylation of tert-Bu (2S)-3-hydroxy-2-(tritylamino)propylcarbamate; the resulting tert-Bu (2S)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-(tritylamino)propylcarbamate underwent hydrolysis to give tert-Bu (2S)-2-amino-3-{[tert-butyl(dimethyl)silyl]oxy}propylcarbamate, which reacted with 4-chloro-3-nitroquinoline to give the corresponding 2-(3-nitroquinolin-4-yl)aminopropylcarbamate, which underwent hydrogenation to give the corresponding 2-(3-aminoquinolin-4-yl)aminopropylcarbamate, which underwent cyclization with 2-chloroethanimidoate; the resulting tert-Bu (2S)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-[2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl]propylcarbamate underwent desilylation and cyclization to give the [10,11-dihydro-8H-[1,4]-oxazino[4',3';1,2]imidazo[4,5-c]quinolin-11-yl]methylcarbamate, which underwent oxidation to give the corresponding 5-oxido derivative, which reacted with ammonium hydroxide to give the [6-amino-10,11-dihydro-8H-[1,4]oxazino[4',3';1,2]imidazo[4,5-c]quinolin-11-yl]methylcarbamate, which underwent hydrolysis to give (11S)-11-(aminomethyl)-10,11-dihydro-8H-[1,4]-oxazino[4',3';1,2]imidazo[4,5-c]quinolin-6-amine, which reacted with methanesulfonyl chloride to give compound II. All the invention compds. were evaluated for their ability to induce cytokine biosynthesis in animals.

AN 2006:796096 CAPLUS <<LOGINID::20061204>>

DN 145:230639

TI Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds as immunomodulators and their preparation, pharmaceutical compositions and use in treatment of viral and neoplastic diseases

IN Griesgraber, George W.; Kshirsagar, Tushar A.; Johannessen, Sarah C.;

Danielson, Michael E.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 215pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006083440	A2	20060810	WO 2005-US47297	20051229

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-640440P P 20041230
US 2005-697256P P 20050707
OS MARPAT 145:230639

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of chiral fused [1,2]imidazo[4,5-c] ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
GI



I



II



III

AB Title compds. I [X = a bond, straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; X' = straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; provided that the sum of the ring C atoms contributed by X and X' = 1-3; Z = O, NH and derivs., N-SO2-NH- and derivs., etc.; X1 = a bond, alk(en/yn)ylene; R1 = (un)substituted alk(en/yn)yl, hetero/aryl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, etc.; or when taken together RA and RB form a (un)substituted fused hetero/aryl ring, or a (un)substituted fused 5 to 7

membered saturated ring; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals (no data) and in the treatment of diseases including viral and neoplastic diseases (no data). For example, II was prepared via cyclocondensation of diamine III (preparation given) with Et 2-chloroethanimidoate•HCl, followed by TBDMS-deprotection in the presence of tetrabutylammonium fluoride/cyclization in THF, oxidation, and amination with NH4OH. Certain I modulated cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system (no data).

AN 2006:677628 CAPLUS <<LOGINID::20061204>>
DN 145:145757
TI Preparation of chiral fused [1,2]imidazo[4,5-c] ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
IN Griesgraber, George W.; Kshirsagar, Tushar A.; Celebi, Abdulaziz A.; Johannessen, Sarah C.; Danielson, Michael E.; Rice, Michael J.; Wurst, Joshua R.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074003	A2	20060713	WO 2005-US47258	20051229

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-640614P P 20041230
US 2005-697257P P 20050707
OS MARPAT 145:145757

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production and use thereof
GI



I

AB The invention relates to the novel carbamoylase-heterocycles which are of interest in the form of potential physiol. active agents (receptor agonists, antagonists and modulators, ferment inhibitors, oncolytics,

antibacterial and antiparasitic agents, etc), to a focused library comprising carbamoylase-heterocycles, a pharmaceutical composition containing said carbamoylase-heterocycles in the form of an active substance and to methods for the production and the use thereof. The inventive carbamoylase-heterocycles are of general formula (I), wherein W is 6-oxopiperazine,[1,4]diazepan, [1,4] tiazepan or [1,4] oxazepan cycle annelated with at least one optionally substituted or optionally condensed heterocycle Q; R1, R2, R3 are independently of each other a hydrogen atom, an inert substituent, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted Ph, an optionally substituted aryl and an optionally substituted heterocycle; Q is pyrrole, pyrazole, imidazole, tiazole, pyrrolidine, indonole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene, thieno[3,2-b]pyrrole, furo[3,2-b]pyrrole, thieno[2,3-b]pyrrole, benzymidasole, pyridine, quinoline or 1,2,3,4-tetrahydroisoquinoline cycle.

AN 2005:1200372 CAPLUS <<LOGINID::20061204>>

DN 143:452852

TI Annelated carbamoylase-heterocycles, focused library, pharmaceutical compositions and methods for the production and use thereof

IN Ivashchenko, Alexander Vasilievich; Vvedensky, Vladimir Yurievich; Ilyn, Aleksei Petrovich; Kysel, Volodymyr Mikhailovich; Khvat, Alexander Viktorovich; Kuzovkova, Yulia Aleksandrovna; Kutepov, Sergey Aleksandrovich; Dmitrieva, Irina Gennadievna; Zolotarev, Denis Anatolievich; Tkachenko, Sergey Yevgenievich; Okun, Ilya Matusovich; Kravchenko, Dmitri Vladimirovich; Kobak, Vladimir Vasilievich; Trifilenkov, Andrei Sergeevich; Mishunina, Yulia Serafimova; Loseva, Marina Vasilievna; Rizhova, Elena Alexandrovna; Parchinsky, Vladislav Zenonovich; Tsirulnikov, Sergey Alexandrovich; Kyselev, Alexandr Sergeevich

PA "Chemical Diversity Research INSTITUTE", Ltd., Russia

SO PCT Int. Appl., 628 pp.
CODEN: PIXXD2

DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005105805	A1	20051110	WO 2005-RU235	20050429
	WO 2005105805	C2	20060119		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	RU 2266906	C1	20051227	RU 2004-113251	20040429
PRAI	RU 2004-113251	A	20040429		

OS MARPAT 143:452852

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of indazole compounds as MMP-9 inhibitors

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted alkyl, etc.; R2 = II, etc.; R6, R61 = H, halo, etc.; Ar = Ph, etc.] were prepared For example, reaction of 1H-indazol-3-ylcarbamic acid Et ester with 4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidine in the presence of KF-alumina followed by treatment with HCl afforded compound III in 66% yield. In MMP-9 (matrix metalloproteinase-9) production inhibition assays, the IC50 value of compound III was 0.79 μM. Compds. I are claimed useful for the treatment of cancer.

AN 2005:902862 CAPLUS <<LOGINID::20061204>>

DN 143:248381

TI Preparation of indazole compounds as MMP-9 inhibitors

IN Takemiya, Akihiro; Nakajo, Masahiro; Oshima, Hisae; Yanagi, Tomotaka; Mochizuki, Mami; Nakamura, Hideo

PA Mitsubishi Pharma Corporation, Japan

SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005077912	A1	20050825	WO 2005-JP1996	20050210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1714961	A1	20061025	EP 2005-710048	20050210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRAI JP 2004-35565 A 20040212
WO 2005-JP1996 W 20050210

OS MARPAT 143:248381

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; X = a bond, alkylene; Z = (un)substituted alkylene; with the proviso that the total number of C atoms contributed by X and Z = 1-3; Y = a bond, SO2, SO2-NH and derivs., CO, etc.; R = halo, OH, alk(en)yl, haloalkyl, alkoxy, alkylthio, NH2 and derivs.; R1 = H, (un)substituted alk(en/yn)yl, hetero/aryl, etc. with proviso; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the

treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation of 1,2-diamine derivative III with chloroacetyl chloride, cyclization of imidazoquinoline, BOC-deprotection, chlorosulfonation of amine (not isolated) with MeSO2Cl, oxidation/amination with NH4OH, and TBDMS-deprotection. Certain I modulated cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system.

AN 2005:638879 CAPLUS <<LOGINID::20061204>>
DN 143:153410
TI Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
IN Kshirsagar, Tushar A.; Griesgraber, George W.; Celebi, Abdulaziz A.; Heppner, Philip D.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066172	A1	20050721	WO 2004-US43474	20041222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004312510	A1	20050721	AU 2004-312510	20041222
	CA 2552101	AA	20050721	CA 2004-2552101	20041222
	EP 1699792	A1	20060913	EP 2004-815538	20041222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRAI	US 2003-533024P	P	20031229		
	WO 2004-US43474	W	20041222		

OS MARPAT 143:153410
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l3 and (cancer or carcinoma or neoplas? or tumor)
           175 L3
        298785 CANCER
        152207 CARCINOMA
        472329 NEOPLAS?
        390780 TUMOR
L14          5 L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)

=> s l3 and (farnesyl or prenyl)
           175 L3
          5219 FARNESYL
          2920 PRENYL
L15          0 L3 AND (FARNESYL OR PRENYL)

=> file uspatfull
```

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    41.35     228.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.75      -3.75

FILE 'USPATFULL' ENTERED AT 10:02:50 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2006 (20061130/PD)
FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)
HIGHEST GRANTED PATENT NUMBER: US7143445
HIGHEST APPLICATION PUBLICATION NUMBER: US2006272066
CA INDEXING IS CURRENT THROUGH 28 Nov 2006 (20061128/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2006 (20061130/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006


=> s l3 and (l5 OR l6 OR l7 OR ANTHRACYCLINE)
            30 L3
          2361 L5
           502 L6
           415 L7
          2587 ANTHRACYCLINE
L16          0 L3 AND (L5 OR L6 OR L7 OR ANTHRACYCLINE)

=> S L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
            30 L3
        123294 CANCER
         43619 CARCINOMA
         35142 NEOPLAS?
         97134 TUMOR
L17          4 L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)

=> D L17 1-4 TI ABS BIB

L17  ANSWER 1 OF 4  USPATFULL on STN
TI     Cyclopropane compounds and pharmaceutical use thereof
AB     The present invention provides a compound having aggrecanase inhibitory
       activity and MMP-13 inhibitory activity, and useful as a therapeutic
       agent for osteoarthritis, rheumatoid arthritis and the like, more
       specifically, a cyclopropane compound of formula (1):    ##STR1##
       wherein R.sup.1 is --(CH.sub.2).sub.m--X--(CH.sub.2).sub.n-A.sup.1 etc.,
       wherein m and n are the same or different and each is 0 to 6, X.sub.1 is
       a single bond, etc. and A.sup.1 is a substituted C.sub.3-14 hydrocarbon
       ring group, etc.; R.sup.2 and R.sup.3 are the same or different and each
       is a hydrogen atom, --(CH.sub.2).sub.p--X.sub.1-(CH.sub.2).sub.q-
       A.sup.2, etc., wherein p and q are the same or different and each is 0
       to 6, X.sub.1 is a single bond, etc. and A.sup.2 is an optionally
       substituted C.sub.3-14 hydrocarbon ring group, etc.; R.sup.4 is
       --CO.sub.2R.sup.9, etc., wherein R.sup.9 is a hydrogen atom, etc.; and
       R.sup.20 and R.sup.21 are the same or different and each is a hydrogen
       atom, --(CH.sub.2).sub.m12--X.sub.12--(CH.sub.2).sub.m12--R.sup.30,
       etc., wherein m12 and m12 are the same or different and each is 0 to 6,
       X.sub.12 is a single bond, etc. and R.sup.30 is a hydrogen atom, etc.;
       or a prodrug thereof or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2006:234369  USPATFULL <<LOGINID::20061204>>
TI     Cyclopropane compounds and pharmaceutical use thereof
IN     Inaba, Takashi, Osaka, JAPAN
```

Haas, Julia, Boulder, CO, UNITED STATES
Shiozaki, Makoto, Osaka, JAPAN
Littmann, Nicole M., Erie, CO, UNITED STATES
Yasue, Katsutaka, Osaka, JAPAN
Andrews, Steven W., Longmont, CO, UNITED STATES
Sakai, Atushi, Osaka, JAPAN
Fryer, Andrew M., Erie, CO, UNITED STATES
Matsuo, Takafumi, Osaka, JAPAN
Laird, Ellen R., Longmont, CO, UNITED STATES
Suma, Akira, Osaka, JAPAN
Shinozaki, Yuichi, Osaka, JAPAN
Hori, Yoshikazu, Osaka, JAPAN
Imai, Hiroto, Osaka, JAPAN
Negoro, Tamotsu, Osaka, JAPAN

PI US 2006199826 A1 20060907
AI US 2004-11773 A1 20041215 (11)
PRAI US 2003-529116P 20031215 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 4 USPATFULL on STN
TI Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
AB Polyazamacrocyclofluoromonoalkylphosphonic acid compounds are disclosed which form inert complexes with Gd, Mn, Fe or La ions. The complexes are useful as contrast agents for diagnostic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:138889 USPATFULL <<LOGINID::20061204>>
TI Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
IN Kiefer, Garry E., Lake Jackson, TX, United States
Sherry, A. Dean, Dallas, TX, United States
PA The Dow Chemical Company, Midland, MI, United States (U.S. corporation)
The University of Texas, Austin, TX, United States (U.S. corporation)
PI US 5834456 19981110
AI US 1996-606162 19960223 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Grumbling, Matthew V.; Assistant Examiner: Sripada, Pavanaram K.
LREP Kimble, Karen L.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 4 USPATFULL on STN
TI Process for preparing polyazamacrocycles
AB A process for preparing polyazamacrocyclic compounds using a nucleophilic imidazoline with

(A) an ethylene oxide or an ethylene carbonate, in an aprotic solvent, followed by intramolecular amination, and then either basic or acidic hydrolysis; or

(B) an electrophilic substrate, in a polar solvent, optionally in the presence of a non-nucleophilic base, to form an intermediate, followed by basic hydrolysis; or

(C) a electrophilic substrate, in a polar solvent, optionally in the presence of a non-nucleophilic base, followed by prolonged heating in a polar solvent or by treatment with a peroxide solution, followed by basic hydrolysis to form a urea, then basic hydrolysis under pressure; and

separating the desired polyazamacrocycle. The compounds so prepared are useful in pharmaceutical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:118663 USPATFULL <<LOGINID::20061204>>
TI Process for preparing polyazamacrocycles
IN Athey, Phillip S., Lake Jackson, TX, United States
Kiefer, Garry E., Lake Jackson, TX, United States
PA The Dow Chemical Company, Midland, MI, United States (U.S. corporation)
PI US 5587451 19961224
AI US 1994-320620 19941007 (8)
RLI Continuation-in-part of Ser. No. US 1993-158654, filed on 26 Nov 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Seidleck, James J.; Assistant Examiner: Truong, Duc
LREP Kimble, Karen L.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 955
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 4 USPATFULL on STN
TI (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
AB Novel (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives, compositions containing the same, and methods of treating androgen dependent disorders in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 89:69782 USPATFULL <<LOGINID::20061204>>
TI (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
IN Raeymaekers, Alfons H. M., Beerse, Belgium
Freyne, Eddy J. E., Rumst, Belgium
Sanz, Gerard C., Garges les Gonesse, France
PA Janssen Pharmaceutica N.V., Beerse, Belgium (non-U.S. corporation)
PI US 4859684 19890822
AI US 1987-78435 19870727 (7)
RLI Continuation-in-part of Ser. No. US 1986-907903, filed on 15 Sep 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Whittenbaugh, Robert C.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1,13
DRWN No Drawings
LN.CNT 2906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> S L3 AND (nasopharyngeal)

```
           30 L3
         3484 NASOPHARYNGEAL
L18         0 L3 AND (NASOPHARYNGEAL)

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    143.21     371.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -3.75

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:04:52 ON 04 DEC 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'USPATFULL' AT 10:07:39 ON 04 DEC 2006
FILE 'USPATFULL' ENTERED AT 10:07:39 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    143.21     371.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -3.75

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    143.21     371.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -3.75

FILE 'REGISTRY' ENTERED AT 10:07:49 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     3 DEC 2006  HIGHEST RN 914612-67-2
DICTIONARY FILE UPDATES:    3 DEC 2006  HIGHEST RN 914612-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
```

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10529431generic2.str





ring nodes :
1 2 3 4 5 6 7 8 9 10
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10
exact/norm bonds :
1-2 1-7 2-3 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

L19 STRUCTURE UPLOADED

=> d l19
L19 HAS NO ANSWERS
L19 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l19
SAMPLE SEARCH INITIATED 10:08:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4703 TO ITERATE

42.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 89948 TO 98172
PROJECTED ANSWERS: 2814 TO 4428

L20 50 SEA SSS SAM L19

=> d l20 scan

L20 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 8H-[1,4]Diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine, 9,10,11,12-tetrahydro-9-(2-naphthalenylcarbonyl)-, trifluoroacetate (9CI)
MF C25 H21 N5 O . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L20 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine, 8,9,10,11-tetrahydro-3-(2-methylphenyl)-9-(methylsulfonyl)-, trifluoroacetate (9CI)
MF C21 H21 N5 O2 S . x C2 H F3 O2

CM 1



CM 2



L20 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 6H-Pyrido[3',4':4,5]imidazo[1,2-a][1,4]diazepine-9(10H)-carbothioamide, 1-amino-N-cyclopropyl-7,8-dihydro-3,4-dimethyl- (9CI)
MF C16 H22 N6 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrazino[1,2-a]benzimidazole, 1,2,3,4-tetrahydro-2-[2-(2-methylpropoxy)-5-(methylsulfonyl)benzoyl]- (9CI)
MF C22 H25 N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, N-[3-[(11S)-6-amino-1,2,3,4,8,9,10,11-octahydro-9-(methylsulfonyl)pyrazino[1',2':1,2]imidazo[4,5-c]quinolin-11-yl]propyl]-(9CI)
MF C24 H30 N6 O3 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l19 sss full
FULL SEARCH INITIATED 10:08:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 94403 TO ITERATE

100.0% PROCESSED 94403 ITERATIONS 3412 ANSWERS
SEARCH TIME: 00.00.01

L21 3412 SEA SSS FUL L19

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	538.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'CAPLUS' ENTERED AT 10:08:32 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 3 Dec 2006 (20061203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l21/thu
           355 L21
        835303 THU/RL
L22        140 L21/THU
                 (L21 (L) THU/RL)

=> s l22 and (nasopharyngeal)
          3621 NASOPHARYNGEAL
L23          2 L22 AND (NASOPHARYNGEAL)

=> d l23 1-2 ti abs bib
```

L23 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma
GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.
AN 2004:291952 CAPLUS <<LOGINID::20061204>>

DN 140:315043
TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma
IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel
PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T2	20060105	JP 2004-539385	20030929
	US 2006166907	A1	20060727	US 2005-529431	20050325
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		

OS MARPAT 140:315043

L23 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.
AN 2003:28618 CAPLUS <<LOGINID::20061204>>
DN 139:46523
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined

```
     with a farnesyl-transferase inhibitor
AU   Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak,
     Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid;
     Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.;
     Busson, Pierre
CS   UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
SO   Biochemical Pharmacology (2003), 65(3), 423-433
     CODEN: BCPCA6; ISSN: 0006-2952
PB   Elsevier Science Inc.
DT   Journal
LA   English
RE.CNT  47    THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l22 and (cancer or carcinoma or tumor or neoplas?)
        298785 CANCER
        152207 CARCINOMA
        390780 TUMOR
        472329 NEOPLAS?
L24         45 L22 AND (CANCER OR CARCINOMA OR TUMOR OR NEOPLAS?)

=> d his

     (FILE 'HOME' ENTERED AT 09:57:39 ON 04 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 09:57:50 ON 04 DEC 2006
L1              STRUCTURE UPLOADED
L2            46 S L1
L3          2181 S L1 SSS FULL
L4             0 S DANORUBICIN/CN
               EXP DANORUBICIN/CN
L5             1 S DOXORUBICIN/CN
L6             1 S EPIRUBICIN/CN
L7             1 S IDARUBICIN/CN

     FILE 'CAPLUS' ENTERED AT 09:59:47 ON 04 DEC 2006
L8            13 S L3/THU
L9         18780 S L5-L7
L10            0 S L8 AND L9
L11            0 S L8 AND ANTHRACYCLINE
L12            0 S L3 AND (L5-L7 OR ANTHRACYCLINE)
L13            5 S L8 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L14            5 S L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L15            0 S L3 AND (FARNESYL OR PRENYL)

     FILE 'USPATFULL' ENTERED AT 10:02:50 ON 04 DEC 2006
L16            0 S L3 AND (L5 OR L6 OR L7 OR ANTHRACYCLINE)
L17            4 S L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L18            0 S L3 AND (NASOPHARYNGEAL)

     FILE 'REGISTRY' ENTERED AT 10:07:49 ON 04 DEC 2006
L19              STRUCTURE UPLOADED
L20            50 S L19
L21          3412 S L19 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:08:32 ON 04 DEC 2006
L22          140 S L21/THU
L23            2 S L22 AND (NASOPHARYNGEAL)
L24           45 S L22 AND (CANCER OR CARCINOMA OR TUMOR OR NEOPLAS?)

=> s l24 and (L5 or L6 or L7 or anthracycline)
         16798 L5
          2427 L6
```

```
          1475 L7
          5723 ANTHRACYCLINE
L25          3 L24 AND (L5 OR L6 OR L7 OR ANTHRACYCLINE)

=> d l25 1-3 ti abs bib

L25  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of pharmaceutical compositions containing at least a Cdc25
     phosphatase inhibitor, in particular benzothiazole-4,7-dione,
     benzooxazole-4,7-dione derivatives, naphthoquinones, and related
     compounds, combined with at least another anticancer agent for therapeutic
     use in cancer treatment
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

AB   The invention concerns a product which comprises two components (1) at
     least one heterocyclic dione I [wherein: R1 = H, alkyl, alkoxyalkyl,
     alkylthioalkyl, cycloalkyl, (CH2)-X-Y or (CH2)-Z-NR5R6, indanyl,
     tetralinyl, (un)substituted saturated N/O/S heterocyclyl bound at C; also
     (when W = O) R1 = (un)substituted aryl; R2 = H, alkyl, aralkyl; or NR1R2
     may form a heterocyclic ring; R3 = H, halo, alkyl, haloalkyl, alkoxy,
     alkylthio; R4 = alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, CH2CO2H
     or alkyl esters, CH2CONH2 or CH2NH2 or derivs., (un)substituted aryl or
     heteroaryl; R5, R6 = H, alkyl, aralkyl, or (CH2)nOH in which n = 1-6; or
     R5 = alkoxycarbonyl, haloalkoxycarbonyl, or aralkoxycarbonyl, and R6 = H
     or Me; or NR5R6 = saturated, (un)substituted N-heterocycle; X, Z = alkylene; Y
     = saturated, (un)substituted mono-, di-, or tricyclic carbo- or N/O/S
     heterocycle, or (un)substituted carbo- or heterocyclic aryl; and W = O or
     S] or A-B-N(W)-X-Y [A = (un)substituted Ph, naphthyl; B = CO, NHCO(CH2)n,
     (CH2)p; n = 0-3; p = 0-1; W = H, alkyl; X = (Ch2)q, (CH2)qNH, CO(CH2)r; q
     = 1-6; r = 0-6; or N(W)-X = (un)substituted piperazine; Y =
     (un)substittued Ph, SO2-alkyl, SO2-haloalkyl, etc.] and their
     pharmaceutically acceptable salts, combined with (2) at least one other
     anticancer agent for simultaneously, sep. or prolonged therapeutic use in
     cancer treatment.  Specifically, I is combined with (a) DNA base
     analogs, e.g. 5-fluorouracyl; (b) topoisomerase type I and/or II
     inhibitors, e.g. camptothecin and analogs, doxorubicin, or amsacrine; (c)
     compds. interacting with the cellular spindle, e.g. Taxol; (d) compds.
     acting on the cytoskeleton, e.g. vinblastin; (e) G heterotrimeric protein
     inhibitors II [X = R12; Y = R8; or X and Y may form a 6-membered ring with
     X-Y = CH(R8)-CH(R9); R1 = H, alkyl, cyclo/alkylthio; R2, R3 =
     independently H, cyclo/alkyl; R4 = H2, O; R5 = H, (un)substituted
     alk(en/yn)yl, cycloalk(en/yn)yl, aryl, etc.; R6, R7 = H, (un)substituted
     alk(en/yn)yl, cycloalk(en/yn)yl, heterocyclyl, etc.; R8, R9 =
     independently H, (un)substituted aryl, heterocyclyl, etc.; R12 = NR9, S,
     O; and their pharmaceutically acceptable salts]; (f) prenyltransferase,
     especially farnesyltransferase inhibitors III [A = (CR10)n1; n10 = 0-1; X =
     (CHR11)n3(CH2)n4Z(CH2)n5; Z = O, S, NH and derivs.; n3 = 0-1; n4, n5 =
     independently 0-3; Y = CO, CH2, CS, or a bond; R1 = (un)substituted
     imidazol-5-yl, 1,2,3-triazolyl, pyridinyl, etc.; R3 = H, alkyl, aryl,
     heterocyclyl, etc.; R4, R5 = independently H, (un)substituted cyclo/alkyl,
     aryl, heterocyclyl; or R4CCR5 = aryl; R6 = H, (un)substituted alkyl, aryl,
     arylalkyl, etc; R7 = H, :O, :S, (un)substituted cyclo/alkyl, aryl,
     heterocyclyl, etc.; R10 = C; R11 = H, (un)substituted alkyl, aryl and
     their pharmaceutically acceptable salts].  I is also combined with (g) CDK
     inhibitors IV [A = H, halo, formyl, CN, NO2, etc.; X = H, alkylthio,
     alkylthioxo, etc.; Y = NH, O; = a bond, alkylthio/alkyl; Ar =
     (un)substituted arylcarbocyclyl, arylheterocyclyl; and their
     pharmaceutically acceptable salts]; (h) alkylation agents, e.g. cisplatin;
     (i) folic acid antagonists, e.g. methotrexate; and (j) inhibitors of DNA
```

synthesis and cellular division, e.g. mitomycin. Nearly 200 Cdc25 phosphatase inhibitors are prepared and 20 assocns. tested for their antiproliferative activity. Thus,V•HCl (138-140°) was prepared in 2 steps from N,N-dimethylethylenediamine and 5-methoxy-2-methyl-4,7-dioxobenzothiazole. Most compds. I inhibited the phosphatase activity of purified recombinant Cdc25-C in vitro with IC50 values of ≤ 10 μM. Most compds. had IC50 values of ≤ 10 μM against proliferation of human cancer cell lines Mia-Paca2 and DU-145 in vitro. V•HCl was tested for cell proliferation inhibition activity [only 14% of cells lived when combined with VI (vs. colon cancer HT-29 cells)].

AN 2005:610 CAPLUS <<LOGINID::20061204>>
DN 142:93811
TI Preparation of pharmaceutical compositions containing at least a Cdc25 phosphatase inhibitor, in particular benzothiazole-4,7-dione, benzooxazole-4,7-dione derivatives, naphthoquinones, and related compounds, combined with at least another anticancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire; Brezak Pannetier, Marie Christine
PA Societe de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SO Fr. Demande, 135 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2856688	A1	20041231	FR 2003-7649	20030625
	CA 2530668	AA	20050106	CA 2004-2530668	20040624
	WO 2005000852	A2	20050106	WO 2004-FR1586	20040624
	WO 2005000852	A3	20050630		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1641453	A2	20060405	EP 2004-767442	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	FR 2003-7649	A	20030625		
	WO 2004-FR1586	W	20040624		

OS MARPAT 142:93811
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma
GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 CAPLUS <<LOGINID::20061204>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T2	20060105	JP 2004-539385	20030929
	US 2006166907	A1	20060727	US 2005-529431	20050325
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		

OS MARPAT 140:315043

L25 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the

mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN 2003:28618 CAPLUS <<LOGINID::20061204>>
DN 139:46523
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre
CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
SO Biochemical Pharmacology (2003), 65(3), 423-433
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l24 and (farnesyl(w)transferase)
5219 FARNESYL
53811 TRANSFERASE
883 FARNESYL(W)TRANSFERASE
L26 4 L24 AND (FARNESYL(W)TRANSFERASE)

=> d l26 1-4 ti abs bib

L26 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma
GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising

one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 CAPLUS <<LOGINID::20061204>>
DN 140:315043
TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma
IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel
PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T2	20060105	JP 2004-539385	20030929
	US 2006166907	A1	20060727	US 2005-529431	20050325
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		

OS MARPAT 140:315043

L26 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically

expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN 2003:28618 CAPLUS <<LOGINID::20061204>>
DN 139:46523
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Grégoire; Huang, Dolly P.; Busson, Pierre
CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
SO Biochemical Pharmacology (2003), 65(3), 423-433
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
AB The invention provides a product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent, in particular a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous, sep., or prolonged therapeutic use in cancer treatment.
AN 2001:359845 CAPLUS <<LOGINID::20061204>>
DN 134:361346
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas; Morgan, Barry
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001034203	A1	20010517	WO 2000-FR3098	20001108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2800616	A1	20010511	FR 1999-14037	19991109
FR 2800616	B1	20020118		
FR 2803524	A1	20010713	FR 2000-104	20000106
FR 2803524	B1	20020419		
CA 2390317	AA	20010517	CA 2000-2390317	20001108
EP 1233787	A1	20020828	EP 2000-976116	20001108
EP 1233787	B1	20041208		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200203241	A2	20030228	HU 2002-3241	20001108
JP 2003513940	T2	20030415	JP 2001-536200	20001108

	EP 1430934	A1	20040623	EP 2004-75491	20001108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 284224	E	20041215	AT 2000-976116	20001108
	PT 1233787	T	20050429	PT 2000-976116	20001108
	ES 2234692	T3	20050701	ES 2000-976116	20001108
	US 7034024	B1	20060425	US 2002-129569	20020621
	US 2006074078	A1	20060406	US 2005-272304	20051110
PRAI	FR 1999-14037	A	19991109		
	FR 2000-104	A	20000106		
	EP 2000-976116	A3	20001108		
	WO 2000-FR3098	W	20001108		
	US 2002-129569	A3	20020621		

OS MARPAT 134:361346

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of amino acid heterobicyclic amide derivatives as farnesyl transferase inhibitors

GI



I



II



III

AB Title compds. I and II [R1 = H, lower alkyl, lower alkylthio; R1R2 = CH2, CO, CMe2; R2, R3 = independently H, lower alkyl, cycloalkyl; R4 = H2, O; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6, R7 = independently H, CONHCHR13CO2R14, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6R7 = fused aryl or heterocyclyl; R8, R9 = independently H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R8, R9 = fused aryl or heterocyclyl;X = NR9, S, O; R13 = (un)substituted lower alkyl; R14 = H, lower alkyl], and pharmaceutically acceptable salts thereof are capable of inhibiting the activity of farnesyl transferase.
Thus, tetrahydroimidazo[1,2a]pyrazine III, prepared in 6 steps from Cbz-L-Nle-OH (Cbz = PhCH2O2C), BrCH2COC6H4OMe-2, BrCH2CO2Et, and Boc-L-Cys(CPh3)-OH (Boc = Me3CO2C), displayed antiproliferative activities of 6.25-12.5 μM, 12.5 μM, 10-30 μM, and 12.5-25 μM against A-427 lung carcinomas, HT-29 colon adenocarcinomas, Calu-1 lung

carcinomas, and MIA PaCa pancreatic cancer cells, resp.
AN 1997:568118 CAPLUS <<LOGINID::20061204>>
DN 127:248417
TI Preparation of amino acid heterobicyclic amide derivatives as farnesyl transferase inhibitors
IN Gordon, Thomas D.; Morgan, Barry A.
PA Biomeasure Incorporated, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9730053	A1	19970821	WO 1997-US2651	19970214
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 2002013319	A1	20020131	US 1996-752546	19961120
	US 6673927	B2	20040106		
	CA 2245823	AA	19970821	CA 1997-2245823	19970214
	CA 2245823	C	20060801		
	AU 9719645	A1	19970902	AU 1997-19645	19970214
	AU 716636	B2	20000302		
	ZA 9701254	A	19980714	ZA 1997-1254	19970214
	EP 904274	A1	19990331	EP 1997-907717	19970214
	EP 904274	B1	20050525		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1216545	A	19990512	CN 1997-193864	19970214
	JP 2001500838	T2	20010123	JP 1997-529596	19970214
	TW 432066	B	20010501	TW 1997-86101769	19970214
	RU 2201931	C2	20030410	RU 1998-117378	19970214
	AT 296303	E	20050615	AT 1997-907717	19970214
	PT 904274	T	20051031	PT 1997-907717	19970214
	ES 2242212	T3	20051101	ES 1997-907717	19970214
	US 2003119864	A1	20030626	US 2002-273735	20021018
	US 7022704	B2	20060404		
	US 2006079530	A1	20060413	US 2005-287996	20051128
	US 2006252760	A1	20061109	US 2006-442758	20060530
PRAI	US 1996-49997P	P	19960216		
	US 1996-602438	A	19960216		
	US 1996-752546	A	19961120		
	WO 1997-US2651	W	19970214		
	US 2002-273735	A1	20021018		
	US 2005-287996	A1	20051128		

OS MARPAT 127:248417

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.51	583.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.75	-10.50

FILE 'USPATFULL' ENTERED AT 10:11:41 ON 04 DEC 2006

```
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2006 (20061130/PD)
FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)
HIGHEST GRANTED PATENT NUMBER: US7143445
HIGHEST APPLICATION PUBLICATION NUMBER: US2006272066
CA INDEXING IS CURRENT THROUGH 28 Nov 2006 (20061128/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2006 (20061130/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006


=> s l21
L27        200 L21

=> s l27 and (anthtacycline or L5 or L6 or L7)
             1 ANTHTACYCLINE
          2361 L5
           502 L6
           415 L7
L28          1 L27 AND (ANTHTACYCLINE OR L5 OR L6 OR L7)

=> d l28 ti abs bib

L28  ANSWER 1 OF 1  USPATFULL on STN
TI     Composition for the treatment of nasopharyngeal carcinoma and method of
       use thereof
AB     Disclosed is a novel drug combination which is useful for the treatment
       of nasopharyngeal carcinoma, said novel drug combination comprising one
       or more of a farnesyl transferase inhibitor and one or more of an
       anthracyline.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2006:196151  USPATFULL <<LOGINID::20061204>>
TI     Composition for the treatment of nasopharyngeal carcinoma and method of
       use thereof
IN     Prevost, Gregoire, Antony, FRANCE
       Busson, Pierre, Antony, FRANCE
       Vicat, Jean-Michel, Saint-Marcel-bel-accueil, FRANCE
PI     US 2006166907       A1  20060727
AI     US 2003-529431      A1  20030929 (10)
       WO 2003-IB4922          20030929
                               20050325  PCT 371 date
PRAI   US 2002-414103P     20020927 (60)
DT     Utility
FS     APPLICATION
LREP   Brian R Morrill, Biomeasure Incorporated, 27 Maple Street, Milford, MA,
       01757-3650, US
CLMN   Number of Claims: 33
ECL    Exemplary Claim: 1
DRWN   6 Drawing Page(s)
LN.CNT 1689
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s l27 and (cnacer or carcinoma or tumor or neoplas?)
            21 CNACER
         43619 CARCINOMA
         97134 TUMOR
         35142 NEOPLAS?
L29         52 L27 AND (CNACER OR CARCINOMA OR TUMOR OR NEOPLAS?)

=> s l27 and (cancer or carcinoma or tumor or neoplas?)
        123294 CANCER
         43619 CARCINOMA
```

```
         97134 TUMOR
         35142 NEOPLAS?
L30         66 L27 AND (CANCER OR CARCINOMA OR TUMOR OR NEOPLAS?)

=> s l30 not py>2004
        836108 PY>2004
L31         22 L30 NOT PY>2004

=> d l30 and nasopharyngeal
'AND' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
'NASOPHARYNGEAL' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
             IPCI-2, IPCR, EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR,
             EXF, ARTU, OS, CC, SX, ST, IT
IPC.TAB ---- IPC in tabular format
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
```

```
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2,
             IPCR, EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             IPCI, IPCI-2, IPCR

SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR(random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
ENTER DISPLAY FORMAT (STD):ti

L30  ANSWER 1 OF 66  USPATFULL on STN
TI     Systems and Methods to Treat Pain Locally


=> s l30 and nasopharyngeal
          3484 NASOPHARYNGEAL
L32          1 L30 AND NASOPHARYNGEAL

=> d l13 ti as bib
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:n


=> d l30 ti as bib
'AS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
             IPCI-2, IPCR, EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
```

```
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR,
             EXF, ARTU, OS, CC, SX, ST, IT
IPC.TAB ---- IPC in tabular format
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2,
             IPCR, EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             IPCI, IPCI-2, IPCR

SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR(random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
ENTER DISPLAY FORMAT (STD):ti abs bib

L30  ANSWER 1 OF 66  USPATFULL on STN
TI     Systems and Methods to Treat Pain Locally
AB     Disclosed herein are systems and methods for contributing to the local
       treatment of pain. More specifically, the disclosed systems and methods
       contribute to the local treatment pain by inhibiting the NFκB
       family of transcription factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2006:295930  USPATFULL <<LOGINID::20061204>>
TI     Systems and Methods to Treat Pain Locally
IN     Burright, Eric N., 899 Oak Court, Eagan, MN, UNITED STATES  55123
       Shafer, Lisa L., 3768 Ambercrombie Lane, Stillwater, MN, UNITED STATES
       55082
       McKay, Bill, 3870 McElrie Cove, Memphis, TN, UNITED STATES  38133
       Zanella, John, 307 Steadman Lane, Cordova, TN, UNITED STATES  38018
PA     MEDTRONIC, INC., Minneapolis, MN, UNITED STATES (U.S. corporation)
PI     US 2006253100       A1  20061109
AI     US 2006-460012      A1  20060726 (11)
RLI    Continuation-in-part of Ser. No. US 2004-972157, filed on 22 Oct 2004,
```

PENDING
DT Utility
FS APPLICATION
LREP PRESTON GATES & ELLIS LLP, 1900 MAIN STREET, SUITE 600, IRVINE, CA, 92614-7319, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1016
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l31 1-22 ti

L31 ANSWER 1 OF 22 USPATFULL on STN
TI 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists

L31 ANSWER 2 OF 22 USPATFULL on STN
TI Imidazolyl derivatives

L31 ANSWER 3 OF 22 USPATFULL on STN
TI Inhibitor of cox

L31 ANSWER 4 OF 22 USPATFULL on STN
TI Methods and compositions for treating inflammatory disorders of the airways

L31 ANSWER 5 OF 22 USPATFULL on STN
TI Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment

L31 ANSWER 6 OF 22 USPATFULL on STN
TI Imidazoquinoxaline protein tyrosine kinase inhibitors

L31 ANSWER 7 OF 22 USPATFULL on STN
TI Benzhydryl derivatives

L31 ANSWER 8 OF 22 USPATFULL on STN
TI Tricyclic compounds and their uses

L31 ANSWER 9 OF 22 USPATFULL on STN
TI Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

L31 ANSWER 10 OF 22 USPATFULL on STN
TI Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein

L31 ANSWER 11 OF 22 USPATFULL on STN
TI TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES

L31 ANSWER 12 OF 22 USPATFULL on STN
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists

L31 ANSWER 13 OF 22 USPATFULL on STN
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists

L31 ANSWER 14 OF 22 USPATFULL on STN
TI FARNESYL TRANSFERASE INHIBITORS

L31 ANSWER 15 OF 22 USPATFULL on STN
TI Vitronectin receptor antagonists

L31 ANSWER 16 OF 22 USPATFULL on STN
TI Imidazoquinoxaline protein tyrosine kinase inhibitors

L31 ANSWER 17 OF 22 USPATFULL on STN
TI Vitronectin receptor antagonists

L31 ANSWER 18 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the vitronectin receptor

L31 ANSWER 19 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor

L31 ANSWER 20 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor

L31 ANSWER 21 OF 22 USPATFULL on STN
TI Substituted-1,4-diazepines

L31 ANSWER 22 OF 22 USPATFULL on STN
TI (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders

=> d l31 5 8 9 11 12 13 14 16 18 19 20 21 ti abs bib

L31 ANSWER 5 OF 22 USPATFULL on STN
TI Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment
AB The invention concerns a product comprising at least mikanolide, dihydromikanolide or an analogue thereof combined with at least another anti-cancer agent for simultaneous, separate or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analogue thereof is combined with enzymatic inhibitors such as G heterotrimeric protein inhibitors or alkylating agents such as cis-platinum.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:179075 USPATFULL <<LOGINID::20061204>>
TI Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire, Antony, FRANCE
Coulomb, Helene, Igny, FRANCE
Lavergne, Olivier, Palaiseau, FRANCE
Lanco, Christophe, Dourdan, FRANCE
Teng, Beng Poon, Gif-Sur-Yvette, FRANCE
PI US 2004138245 A1 20040715
AI US 2003-478387 A1 20031211 (10)
WO 2002-FR1800 20020529
PRAI FR 2001-7104 20010530
DT Utility
FS APPLICATION
LREP Muserlian, Lucas and Mercanti, 475 Park Avenue South, New York, NY, 10016
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 8 OF 22 USPATFULL on STN
TI Tricyclic compounds and their uses
AB Novel tricyclic compounds are found to be useful for the treatment or

prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:232600 USPATFULL <<LOGINID::20061204>>
TI Tricyclic compounds and their uses
IN Gong, Baoqing, Shoreline, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Coon, Michael, Seattle, WA, UNITED STATES
PI US 2003162801 A1 20030828
AI US 2003-349935 A1 20030124 (10)
RLI Continuation of Ser. No. US 2000-725016, filed on 29 Nov 2000, PENDING
DT Utility
FS APPLICATION
LREP WILLEM F. GADIANO, ESQ., McDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2717
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 9 OF 22 USPATFULL on STN
TI Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AB The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:146816 USPATFULL <<LOGINID::20061204>>
TI Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
IN Edmondson, Scott D., New York, NJ, UNITED STATES
Fisher, Michael H., Ringoes, NJ, UNITED STATES
Kim, Dooseop, Westfield, NJ, UNITED STATES
Maccoss, Malcolm, Freehold, NJ, UNITED STATES
Parmee, Emma R., Scotch Plains, NJ, UNITED STATES
Weber, Ann E., Scotch Plains, NJ, UNITED STATES
Xu, Jinyou, Scotch Plains, NJ, UNITED STATES
PI US 2003100563 A1 20030529
US 6699871 B2 20040302
AI US 2002-189603 A1 20020705 (10)
PRAI US 2001-303474P 20010706 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 11 OF 22 USPATFULL on STN
TI TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES
AB Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:192140 USPATFULL <<LOGINID::20061204>>
TI TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES
IN Gong, Baoqing, Shoreline, WA, UNITED STATES
Klein, J. Peter, Vashon, WA, UNITED STATES
Coon, Michael, Seattle, WA, UNITED STATES
PA Cell Therapeutics, Inc. (U.S. corporation)
PI US 2002103211 A1 20020801
US 6586429 B2 20030701
AI US 2000-725016 A1 20001129 (9)
DT Utility
FS APPLICATION
LREP WILLEM F. GADIANO, ESQ., MCDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 12 OF 22 USPATFULL on STN
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists
AB The present invention relates to 2-Mesitylsulfonylamino-3-{3'[(pyridinylamino)methyl][1,1-biphenyl]-4-yl}propanoic acid, pharmaceutical compositions thereof, their preparation, their use in the treatment of cancer, arteriosclerosis, restenosis, osteolytic disorders, ophthalmic disorders, and their use as integrin antagonists. The compounds according to the invention have the formula (I): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:175171 USPATFULL <<LOGINID::20061204>>
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists
IN Albers, Markus, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Urbahns, Klaus, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Vaupel, Andrea, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Stelte-Ludwig, Beatrix, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Gerdes, Christoph, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Stahl, Elke, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
Keldenich, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Brueggemeier, Ulf, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Lustig, Klemens, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PA Beiersdorf AG, Hamburg, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6420396 B1 20020716
AI US 1999-464237 19991215 (9)
PRAI US 1999-172217P 19991019 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: McKenzie, Thomas
LREP Norris McLaughlin & Marcus
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 13 OF 22 USPATFULL on STN
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists
AB The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of

pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) ##STR1##

wherein

R.sup.1, R.sup.2, U, V, A, B, W, R.sup.3, C and R.sup.4 have the meaning as defined in the claims.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:27613 USPATFULL <<LOGINID::20061204>>
TI Biphenyl and biphenyl-analogous compounds as integrin antagonists
IN Albers, Markus, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Urbahns, Klaus, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Vaupel, Andrea, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Harter, Michael, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Schmidt, Delf, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Stelte-Ludwig, Beatrix, Wulfrath, GERMANY, FEDERAL REPUBLIC OF
Gerdes, Christoph, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Stahl, Elke, Bergisch Gladbach, GERMANY, FEDERAL REPUBLIC OF
Keldenich, Jorg, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Brueggemeier, Ulf, Leverkusen, GERMANY, FEDERAL REPUBLIC OF
Lustig, Klemens, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PI US 2002016461 A1 20020207
US 6677360 B2 20040113
AI US 2001-828514 A1 20010406 (9)
RLI Division of Ser. No. US 1999-464237, filed on 15 Dec 1999, PENDING
PRAI US 1998-172225P 19981216 (60)
DT Utility
FS APPLICATION
LREP NORRIS MCLAUGHLIN & MARCUS, P.A., 660 WHITE PLAINS ROAD, TARRYTOWN, NY, 10591-5144
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 14 OF 22 USPATFULL on STN
TI FARNESYL TRANSFERASE INHIBITORS
AB A family of compounds capable of inhibiting the activity of farnesyl transferase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:22483 USPATFULL <<LOGINID::20061204>>
TI FARNESYL TRANSFERASE INHIBITORS
IN GORDON, THOMAS D., MEDWAY, MA, UNITED STATES
MORGAN, BARRY A., FRANKLIN, MA, UNITED STATES
PI US 2002013319 A1 20020131
US 6673927 B2 20040106
AI US 1996-752546 A1 19961120 (8)
RLI Continuation of Ser. No. US 1996-602438, filed on 16 Feb 1996, ABANDONED
DT Utility
FS APPLICATION
LREP Brian R Morrill, Biomeasure Incorporated, 27 Maple Street, Milford, MA, 01757-3650
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 16 OF 22 USPATFULL on STN

TI Imidazoquinoxaline protein tyrosine kinase inhibitors
AB Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:79158 USPATFULL <<LOGINID::20061204>>
TI Imidazoquinoxaline protein tyrosine kinase inhibitors
IN Barrish, Joel C., Richboro, PA, United States
Spergel, Steven H., Warrington, PA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6239133 B1 20010529
AI US 2000-566002 20000505 (9)
RLI Continuation of Ser. No. US 1998-94297, filed on 15 Jun 1998
PRAI US 1997-56797P 19970825 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Kifle, Bruck; Assistant Examiner: Liu, Hong
LREP Hermenau, Ronald S.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 18 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the vitronectin receptor
AB A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:14798 USPATFULL <<LOGINID::20061204>>
TI Tricyclic inhibitors of the vitronectin receptor
IN Blackburn, Brent K., San Francisco, CA, United States
Robarge, Kirk, San Francisco, CA, United States
Somers, Todd C., Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5716951 19980210
AI US 1995-438143 19950508 (8)
RLI Division of Ser. No. US 1994-313069, filed on 29 Sep 1994, now patented, Pat. No. US 5602173 And a continuation-in-part of Ser. No. US 1993-99019, filed on 29 Jul 1993, now patented, Pat. No. US 5493020
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.
LREP Winter, Daryl B.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3731
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 19 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
AB A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided

in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:2162 USPATFULL <<LOGINID::20061204>>
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
IN Blackburn, Brent K., San Francisco, CA, United States
Robarge, Kirk, San Francisco, CA, United States
Somers, Todd C., Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5705890 19980106
WO 9504057 19950209
AI US 1994-313069 19940926 (8)
WO 1994-US7989 19940715
19940926 PCT 371 date
19940926 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1993-99019, filed on 29 Jul 1993, now patented, Pat. No. US 5493020, issued on 20 Feb 1996
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.
LREP Winter, Daryl B.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 20 OF 22 USPATFULL on STN
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
AB A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:14918 USPATFULL <<LOGINID::20061204>>
TI Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
IN Blackburn, Brent K., San Francisco, CA, United States
Robarge, Kirk, San Francisco, CA, United States
Somers, Todd C., Montara, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5493020 19960220
AI US 1993-99019 19930729 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.
LREP Winter, Daryl B.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L31 ANSWER 21 OF 22 USPATFULL on STN
TI Substituted-1,4-diazepines
AB The invention relates to new 1,4-diazepines of the general formula ##STR1## in which R.sub.1, R.sub.2 R.sub.3, X and A have the meaning

indicated in the specification.

The new compounds are intended for use for the treatment of pathological states and diseases in which PAF (platelet activating factor) is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 92:42897 USPATFULL <<LOGINID::20061204>>

TI Substituted-1,4-diazepines

IN Harreus, Albrecht, Ingelheim am Rhein, Germany, Federal Republic of
Weber, Karl-Heinz, Gau-Algesheim, Germany, Federal Republic of
Stransky, Werner, Gau-Algesheim, Germany, Federal Republic of
Walther, Gerhard, Bingen, Germany, Federal Republic of
Muacevic, Gojko, Ingelheim am Rhein, Germany, Federal Republic of
Stenzel, Jorge C., Munich, Germany, Federal Republic of
Bechtel, Wolf-Dietrich, Appenheim, Germany, Federal Republic of

PA Boehringer Ingelheim KG, Ingelheim am Rhein, Germany, Federal Republic of (non-U.S. corporation)

PI US 5116971 19920526

AI US 1990-584815 19900919 (7)

RLI Continuation of Ser. No. US 1987-33966, filed on 1 Apr 1987, now abandoned

PRAI DE 1986-3610848 19860401

DT Utility

FS Granted

EXNAM Primary Examiner: Bond, Robert T.

LREP Frankhouser, D. E., Timbers, M-E. M., Stempel, A. R.

CLMN Number of Claims: 32

ECL Exemplary Claim: 1,25

DRWN No Drawings

LN.CNT 1544

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'USPATFULL' AT 10:48:53 ON 04 DEC 2006
FILE 'USPATFULL' ENTERED AT 10:48:53 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)s

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   104.88     687.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -10.50

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   104.88     687.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -10.50

FILE 'CAPLUS' ENTERED AT 10:48:58 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Dec 2006  VOL 145 ISS 24
FILE LAST UPDATED: 3 Dec 2006  (20061203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s (nasopharyngeal(w)carcinoma)
          3621 NASOPHARYNGEAL
        152207 CARCINOMA
L33       2061 (NASOPHARYNGEAL(W)CARCINOMA)

=> s l33 and (farnesyl(w)transferase)
          5219 FARNESYL
         53811 TRANSFERASE
           883 FARNESYL(W)TRANSFERASE
L34          2 L33 AND (FARNESYL(W)TRANSFERASE)

=> d l34 1-2 ti abs bib

L34  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Compositions containing farnesyl transferase
     inhibitors for the treatment of nasopharyngeal carcinoma
```

GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 CAPLUS <<LOGINID::20061204>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T2	20060105	JP 2004-539385	20030929
	US 2006166907	A1	20060727	US 2005-529431	20050325
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		

OS MARPAT 140:315043

L34 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much

more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN 2003:28618 CAPLUS <<LOGINID::20061204>>
DN 139:46523
TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre
CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
SO Biochemical Pharmacology (2003), 65(3), 423-433
CODEN: BCPCA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l33 and (prenyl(w)transferase)
          2920 PRENYL
         53811 TRANSFERASE
           144 PRENYL(W)TRANSFERASE
L35          0 L33 AND (PRENYL(W)TRANSFERASE)

=> s (Epstein(w)barr) (farnesyl(w)transferase)
MISSING OPERATOR BARR) (FARNESYL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (Epstein(w)barr) and (farnesyl(w)transferase)
         12295 EPSTEIN
         11835 BARR
         11404 EPSTEIN(W)BARR
          5219 FARNESYL
         53811 TRANSFERASE
           883 FARNESYL(W)TRANSFERASE
L36          1 (EPSTEIN(W)BARR) AND (FARNESYL(W)TRANSFERASE)

=> d l31
YOU HAVE REQUESTED DATA FROM FILE 'USPATFULL' - CONTINUE? (Y)/N:n


=> d l36 ti
```

```
L36  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Apoptosis and TRAF-1 cleavage in Epstein-Barr
     virus-positive nasopharyngeal carcinoma cells treated with doxorubicin
     combined with a farnesyl-transferase inhibitor


=> d his

     (FILE 'HOME' ENTERED AT 09:57:39 ON 04 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 09:57:50 ON 04 DEC 2006
L1             STRUCTURE UPLOADED
L2            46 S L1
L3          2181 S L1 SSS FULL
L4             0 S DANORUBICIN/CN
               EXP DANORUBICIN/CN
L5             1 S DOXORUBICIN/CN
L6             1 S EPIRUBICIN/CN
L7             1 S IDARUBICIN/CN

     FILE 'CAPLUS' ENTERED AT 09:59:47 ON 04 DEC 2006
L8            13 S L3/THU
L9         18780 S L5-L7
L10            0 S L8 AND L9
L11            0 S L8 AND ANTHRACYCLINE
L12            0 S L3 AND (L5-L7 OR ANTHRACYCLINE)
L13            5 S L8 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L14            5 S L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L15            0 S L3 AND (FARNESYL OR PRENYL)

     FILE 'USPATFULL' ENTERED AT 10:02:50 ON 04 DEC 2006
L16            0 S L3 AND (L5 OR L6 OR L7 OR ANTHRACYCLINE)
L17            4 S L3 AND (CANCER OR CARCINOMA OR NEOPLAS? OR TUMOR)
L18            0 S L3 AND (NASOPHARYNGEAL)

     FILE 'REGISTRY' ENTERED AT 10:07:49 ON 04 DEC 2006
L19            STRUCTURE UPLOADED
L20           50 S L19
L21         3412 S L19 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:08:32 ON 04 DEC 2006
L22          140 S L21/THU
L23            2 S L22 AND (NASOPHARYNGEAL)
L24           45 S L22 AND (CANCER OR CARCINOMA OR TUMOR OR NEOPLAS?)
L25            3 S L24 AND (L5 OR L6 OR L7 OR ANTHRACYCLINE)
L26            4 S L24 AND (FARNESYL(W)TRANSFERASE)

     FILE 'USPATFULL' ENTERED AT 10:11:41 ON 04 DEC 2006
L27          200 S L21
L28            1 S L27 AND (ANTHTACYCLINE OR L5 OR L6 OR L7)
L29           52 S L27 AND (CNACER OR CARCINOMA OR TUMOR OR NEOPLAS?)
L30           66 S L27 AND (CANCER OR CARCINOMA OR TUMOR OR NEOPLAS?)
L31           22 S L30 NOT PY>2004
L32            1 S L30 AND NASOPHARYNGEAL

     FILE 'CAPLUS' ENTERED AT 10:48:58 ON 04 DEC 2006
L33         2061 S (NASOPHARYNGEAL(W)CARCINOMA)
L34            2 S L33 AND (FARNESYL(W)TRANSFERASE)
L35            0 S L33 AND (PRENYL(W)TRANSFERASE)
L36            1 S (EPSTEIN(W)BARR) AND (FARNESYL(W)TRANSFERASE)

=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    26.69     714.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -1.50     -12.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:50:56 ON 04 DEC 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:51:47 ON 04 DEC 2006
FILE 'CAPLUS' ENTERED AT 10:51:47 ON 04 DEC 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)f

COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   26.69     714.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -1.50     -12.00

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   26.69     714.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -1.50     -12.00

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:51:55 ON 04 DEC 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (nasopharyngeal(w)carcinoma) and (farnesyl(w)transferase)
          2   FILE CAPLUS
  20 FILES SEARCHED...
          1   FILE DDFU
          1   FILE DRUGU
          1   FILE EMBASE
          1   FILE IFIPAT
  42 FILES SEARCHED...
          1   FILE MEDLINE
          1   FILE PASCAL
          1   FILE SCISEARCH
          2   FILE TOXCENTER
```

```
        11   FILE USPATFULL
         1   FILE USPAT2
  63 FILES SEARCHED...
         1   FILE WPIDS
         1   FILE WPINDEX

  13 FILES HAVE ONE OR MORE ANSWERS,   68 FILES SEARCHED IN STNINDEX

L37  QUE (NASOPHARYNGEAL(W) CARCINOMA) AND (FARNESYL(W) TRANSFERASE)

=> file uspatfull pctfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.83     716.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -12.00

FILE 'USPATFULL' ENTERED AT 10:53:29 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 10:53:29 ON 04 DEC 2006
COPYRIGHT (C) 2006 Univentio

=> s (nasopharyngeal(w)carcinoma) and (farnesyl(w)transferase)
L38         18 (NASOPHARYNGEAL(W) CARCINOMA) AND (FARNESYL(W) TRANSFERASE)

=> d l31 1-18 ti

L31  ANSWER 1 OF 22  USPATFULL on STN
TI     1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists

L31  ANSWER 2 OF 22  USPATFULL on STN
TI     Imidazolyl derivatives

L31  ANSWER 3 OF 22  USPATFULL on STN
TI     Inhibitor of cox

L31  ANSWER 4 OF 22  USPATFULL on STN
TI     Methods and compositions for treating inflammatory disorders of the
       airways

L31  ANSWER 5 OF 22  USPATFULL on STN
TI     Product comprising mikanolide, dihydromikanolide or an analogue thereof
       combine with another anti-cancer agent for therapeutic use in
       cancer treatment

L31  ANSWER 6 OF 22  USPATFULL on STN
TI     Imidazoquinoxaline protein tyrosine kinase inhibitors

L31  ANSWER 7 OF 22  USPATFULL on STN
TI     Benzhydryl derivatives

L31  ANSWER 8 OF 22  USPATFULL on STN
TI     Tricyclic compounds and their uses

L31  ANSWER 9 OF 22  USPATFULL on STN
TI     Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the
       treatment or prevention of diabetes

L31  ANSWER 10 OF 22  USPATFULL on STN
TI     Use of cysteine derivatives for preparing a medicine for treating
       pathologies resulting from the formation of heterotrimeric G protein
```

```
L31  ANSWER 11 OF 22  USPATFULL on STN
TI     TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES

L31  ANSWER 12 OF 22  USPATFULL on STN
TI     Biphenyl and biphenyl-analogous compounds as integrin antagonists

L31  ANSWER 13 OF 22  USPATFULL on STN
TI     Biphenyl and biphenyl-analogous compounds as integrin antagonists

L31  ANSWER 14 OF 22  USPATFULL on STN
TI     FARNESYL TRANSFERASE INHIBITORS

L31  ANSWER 15 OF 22  USPATFULL on STN
TI     Vitronectin receptor antagonists

L31  ANSWER 16 OF 22  USPATFULL on STN
TI     Imidazoquinoxaline protein tyrosine kinase inhibitors

L31  ANSWER 17 OF 22  USPATFULL on STN
TI     Vitronectin receptor antagonists

L31  ANSWER 18 OF 22  USPATFULL on STN
TI     Tricyclic inhibitors of the vitronectin receptor


=> s l31 not py>2004
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms.  L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles.  The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l38 not py>2004
L39           7 L38 NOT PY>2004

=> d l39 1-7 ti

L39  ANSWER 1 OF 7  USPATFULL on STN
TI     Modified "S" antibodies

L39  ANSWER 2 OF 7  USPATFULL on STN
TI     Progression elevated Gene-3 and uses thereof

L39  ANSWER 3 OF 7  USPATFULL on STN
TI     PROGRESSION ELEVATED GENE-3 AND USES THEREOF

L39    ANSWER 4 OF 7      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
TIFR   ANTICORPS ANTI-IL-6, COMPOSITIONS, METHODES ET UTILISATIONS ASSOCIEES

L39    ANSWER 5 OF 7      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL
       CARCINOMA AND METHOD OF USE THEREOF
TIFR   COMPOSITION POUR TRAITER LE CANCER DU NASOPHARYNX ET PROCEDE
       D'UTILISATION CORRESPONDANT

L39    ANSWER 6 OF 7      PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   THERAPEUTIC METHODS USING HERBAL COMPOSITIONS
TIFR   TRAITEMENTS A BASE DE COMPOSITIONS PHYTOTHERAPIQUES

L39    ANSWER 7 OF 7      PCTFULL   COPYRIGHT 2006 Univentio on STN
```

TIEN PROGRESSION ELEVATED GENE-3 AND USES THEREOF
TIFR GENE-3 A PROGRESSION ELEVEE ET SES UTILISATIONS

=> d l39 5 6 7 ti abs bib

L39 ANSWER 5 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA AND METHOD OF USE THEREOF
TIFR COMPOSITION POUR TRAITER LE CANCER DU NASOPHARYNX ET PROCEDE D'UTILISATION CORRESPONDANT
ABEN Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracyline.
ABFR L'invention concerne une nouvelle combinaison de medicaments utilisee pour traiter le cancer du nasopharynx. Cette nouvelle combinaison de medicaments comprend un ou plusieurs inhibiteurs de farnesyl transferase et une ou plusieurs anthracylines.
AN 2004028541 PCTFULL ED 20040414 EW 200415 <<LOGINID::20061204>>
TIEN COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA AND METHOD OF USE THEREOF
TIFR COMPOSITION POUR TRAITER LE CANCER DU NASOPHARYNX ET PROCEDE D'UTILISATION CORRESPONDANT
IN PREVOST, Gregoire, 5, avenue du Canada, F-91966 Les Ulis, FR [FR, FR]; BUSSON, Pierre, 39, rue Camille Desmoulins, F-94805 Ville Juif, FR [FR, FR]; VICAT, Jean-Michel, 39, rue Camille Desmoulins, F-94805 Ville Juif, FR [FR, FR]
PA SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S., 51-53 rue du Docteur Blanche, F-75016 Paris, FR [FR, FR], for all designates States except US; CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE, 3, rue Michel-Ange, F-75794 Paris Cedex 16, FR [FR, FR], for all designates States except US; PREVOST, Gregoire, 5, avenue du Canada, F-91966 Les Ulis, FR [FR, FR], for US only; BUSSON, Pierre, 39, rue Camille Desmoulins, F-94805 Ville Juif, FR [FR, FR], for US only; VICAT, Jean-Michel, 39, rue Camille Desmoulins, F-94805 Ville Juif, FR [FR, FR], for US only
AG HALL, Robert, L., Harrison Goddard Foote, Fountain Precinct, Balm Green, Sheffield S1 2JA, GB
LAF English
LA English
DT Patent
PI WO 2004028541 A2 20040408
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2003-IB4922 A 20030929
PRAI US 2002-60/414,103 20020927

L39 ANSWER 6 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN THERAPEUTIC METHODS USING HERBAL COMPOSITIONS
TIFR TRAITEMENTS A BASE DE COMPOSITIONS PHYTOTHERAPIQUES
ABEN Compositions derived from traditional Chinese herbal medicines, medicinal plants and extracts thereof, are provided for the prevention

and treatment of cancers especially lung cancer, prostate cancer, liver cancer, breast cancer and leukemia. The composition is also useful for treating Helicobacter pylori infection. The composition is also useful for treating or preventing a chronic inflammatory condition. The composition is also useful for treating or preventing cardiovascular disease. The composition is also useful for treating or preventing cerebral vascular disease. The compositions are useful as adjuncts to conventional surgery, chemotherapy or radiotherapy treatments in patients with cancer. Preferred compositions of the invention contain the herbal ingredients Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus Turcz, and Dioscorea bulbifera.

ABFR La presente invention concerne des compositions derivees de la phytopharmacopee chinoise traditionnelle, de l'herboristerie et de leurs extraits, et convenant pour la prevention et le traitement de cancers tels que ceux du poumon, de la prostate, du foie, du sein, et la leucemie. La composition convient egalement au traitement de l'infection par Helicobacter pylori. La composition convient en outre pour le traitement ou la prevention d'un etat inflammatoire chronique, d'une affection cardio-vasculaire, d'une affection cerebro-vasculaire. La composition convient aussi en traitement adventif de la chirurgie conventionnelle, de la chimiotherapie et de la radiotherapie chez les cancereux. Les compositions preferees de l'invention contiennent comme ingredients d'herboristerie les Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus Turcz, et Dioscorea bulbifera.

AN 2002067961 PCTFULL ED 20020916 EW 200236 <<LOGINID::20061204>>
TIEN THERAPEUTIC METHODS USING HERBAL COMPOSITIONS
TIFR TRAITEMENTS A BASE DE COMPOSITIONS PHYTOTHERAPIQUES
IN LIN, Peizhong, Cancer Institute, Chinese Academy of Medical Scien, ce, P.O. Box 2258, Panjiayuan, Chaoyang District, Beijing 100021, CN [CN, CN];
LAM, Stephen, 5512 Wycliffe Road, Vancouver, British Columbia V6T 2E3, CA [CA, CA];
TAI, Joseph, 1082 Adderley Street, North Vancouver, British Columbia V7L 1T3, CA [CA, CA];
TZE, John, Wah, Jun
PA GLOBAL CANCER STRATEGIES LTD., 113-990 Beach Avenue, Vancouver, British Columbia V6E 4M2, CA [CA, CA], for all designates States except US;
TZE, Theresa Chiang, 5724, Montgomery Street, Vancouver, British Columbia V6M 2X4, CA [CA, CA], for US only;
LIN, Peizhong, Cancer Institute, Chinese Academy of Medical Scien, ce, P.O. Box 2258, Panjiayuan, Chaoyang District, Beijing 100021, CN [CN, CN], for US only;
LAM, Stephen, 5512 Wycliffe Road, Vancouver, British Columbia V6T 2E3, CA [CA, CA], for US only;
TAI, Joseph, 1082 Adderley Street, North Vancouver, British Columbia V7L 1T3, CA [CA, CA], for US only
AG ERRATT, Judy, A., Gowling Lafleur Henderson LLP, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3, CA
LAF English
LA English
DT Patent
PI WO 2002067961 A2 20020906
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-CA222 A 20020226

PRAI US 2001-09/793,251 20010226

L39 ANSWER 7 OF 7 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PROGRESSION ELEVATED GENE-3 AND USES THEREOF
TIFR GENE-3 A PROGRESSION ELEVEE ET SES UTILISATIONS
ABEN This invention provides a vector suitable for introduction into a cell, comprising: a) an inducible PEG-3 regulatory region; and b) a gene encoding a product that causes or may be induced to cause the death or inhibition of cancer cell growth. In addition, this invention further provides the above-described vectors, wherein the inducible PEG-3 regulatory region is a promoter. This invention further provides the above-described vectors, wherein the gene encodes an inducer of apoptosis. In addition, this invention provides the above-described vectors, wherein the gene is a tumor suppressor gene. In addition, this invention provides the above-described vectors, wherein the gene encodes a viral replication protein. This invention also provides the above-described vectors, wherein the gene encodes a product toxic to cells or an intermediate to a product toxic to cells. In addition, this invention provides the above-described vectors, wherein the gene encodes a product causing enhanced immune recognition of the cell. This invention further provides the above-described vectors, wherein the gene encodes a product causing the cell to express a specific antigen.
ABFR L'invention concerne un vecteur approprie pour etre introduit dans une cellule, comprenant: a) une region regulatrice inductible de PEG-3; et b) un gene codant un produit provoquant ou susceptible de provoquer la mort des cellules cancereuses ou l'inhibition de leur croissance. En outre, l'invention concerne les vecteurs decrits ci-dessus, dans lesquels la region regulatrice inductible de PEG-3 est un promoteur. L'invention concerne egalement les vecteurs decrits ci-dessus, dans lesquels le gene code un inducteur de l'apoptose. L'invention concerne les vecteurs decrits ci-dessus, dans lesquels le gene est un gene suppresseur de tumeurs. L'invention concerne les vecteurs decrits ci-dessus, dans lesquels le gene code une proteine de replication virale. L'invention concerne les vecteurs decrits ci-dessus, dans lesquels le gene code un produit provoquant une reconnaissance immune amelioree de la cellule. L'invention concerne les vecteurs decrits ci-dessus, dans lesquels le gene code un produit provoquant l'expression d'un antigene specifique par la cellule.
AN 1999049898 PCTFULL ED 20020515 <<LOGINID::20061204>>
TIEN PROGRESSION ELEVATED GENE-3 AND USES THEREOF
TIFR GENE-3 A PROGRESSION ELEVEE ET SES UTILISATIONS
IN FISHER, Paul, B.
PA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
LA English
DT Patent
PI WO 9949898 A1 19991007
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GH GM

```
                    KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
                    CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
                    CG CI CM GA GN GW ML MR NE SN TD TG
AI     WO 1999-US7199       A  19990331
PRAI   US 1998-09/052,753       19980331


=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     6.96     723.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:55:07 ON 04 DEC 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'USPATFULL, PCTFULL' AT 10:57:33 ON 04 DEC 2006
FILE 'USPATFULL' ENTERED AT 10:57:33 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'PCTFULL' ENTERED AT 10:57:33 ON 04 DEC 2006
COPYRIGHT (C) 2006 Univentiof

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     8.39     724.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     8.39     724.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

FILE 'REGISTRY' ENTERED AT 10:57:40 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 DEC 2006  HIGHEST RN 914612-67-2
DICTIONARY FILE UPDATES:   3 DEC 2006  HIGHEST RN 914612-67-2
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s BIM-2001/cn
L40             0 BIM-2001/CN

=> exp BIM-2001/cn
E1              1     BIM 53097/CN
E2              1     BIM 8/CN
E3              0 --> BIM-2001/CN
E4              1     BIM-23246/CN
E5              1     BIM-23255/CN
E6              1     BIMAKALIM/CN
E7              1     BIMAKALIN/CN
E8              1     BIMALONIC ACID/CN
E9              1     BIMALONIC ACID, AMINO-, TETRASODIUM SALT/CN
E10             1     BIMALONIC ACID, BIS(B-HYDROXYETHYL)-, DI-Γ-LACTON
                      E/CN
E11             1     BIMALONIC ACID, BIS(B-HYDROXYETHYL)-, DI-Γ-LACTON
                      E, DIETHYL ESTER/CN
E12             1     BIMALONIC ACID, BIS-(P-NITROPHENOXY)-/CN

=> exp BIM 2001/cn
E1              1     BIM 189/CN
E2              2     BIM 2/CN
E3              1 --> BIM 2001/CN
E4              1     BIM 21009/CN
E5              1     BIM 21009C/CN
E6              1     BIM 22010/CN
E7              1     BIM 22013/CN
E8              1     BIM 22015/CN
E9              1     BIM 22016/CN
E10             1     BIM 23003/CN
E11             1     BIM 23012/CN
E12             1     BIM 23014/CN

=> exp BIM2001/cn
E1              1     BIM-23246/CN
E2              1     BIM-23255/CN
E3              0 --> BIM2001/CN
E4              1     BIMAKALIM/CN
E5              1     BIMAKALIN/CN
E6              1     BIMALONIC ACID/CN
E7              1     BIMALONIC ACID, AMINO-, TETRASODIUM SALT/CN
E8              1     BIMALONIC ACID, BIS(B-HYDROXYETHYL)-, DI-Γ-LACTON
                      E/CN
E9              1     BIMALONIC ACID, BIS(B-HYDROXYETHYL)-, DI-Γ-LACTON
                      E, DIETHYL ESTER/CN
E10             1     BIMALONIC ACID, BIS-(P-NITROPHENOXY)-/CN
E11             1     BIMALONIC ACID, DIBENZOYL-, TETRAETHYL ESTER/CN
E12             1     BIMALONIC ACID, DIIMIDE/CN
```

```
PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 11:08:03 ON 04 DEC 2006
FILE 'REGISTRY' ENTERED AT 11:08:03 ON 04 DEC 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)f

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.20     730.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.20     730.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

FILE 'REGISTRY' ENTERED AT 11:08:09 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     3 DEC 2006  HIGHEST RN 914612-67-2
DICTIONARY FILE UPDATES:    3 DEC 2006  HIGHEST RN 914612-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10529431BIM2001.str
```



chain nodes :
17 22 23 24 26 31 38 39 40 41
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 25 27 28
29 30 32 33 34 35 36 37
chain bonds :
3-23 9-11 16-17 18-22 23-24 23-26 24-25 27-31 31-32 34-38 35-40 38-39
40-41
ring bonds :
1-2 1-7 1-18 2-3 2-21 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10 11-12 11-16
12-13 13-14 14-15 15-16 18-19 19-20 20-21 25-27 25-30 27-28 28-29 29-30
32-33 32-37
33-34 34-35 35-36 36-37
exact/norm bonds :
1-7 2-3 3-4 3-23 4-5 5-6 5-8 6-7 6-10 8-9 9-10 23-26 25-27 25-30 27-28
28-29 29-30 34-38 40-41
exact bonds :
9-11 16-17 18-22 23-24 24-25 27-31 31-32 35-40 38-39
normalized bonds :
1-2 1-18 2-21 11-12 11-16 12-13 13-14 14-15 15-16 18-19 19-20 20-21
32-33
32-37 33-34 34-35 35-36 36-37

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS 23:CLASS 24:CLASS 25:Atom 26:CLASS 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:Atom
33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:CLASS 39:CLASS 40:CLASS 41:CLASS

L41 STRUCTURE UPLOADED

=> d l41
L41 HAS NO ANSWERS
L41 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l41 fam full
FULL SEARCH INITIATED 11:08:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L42 1 SEA FAM FUL L41

=> d l42

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 280775-32-8 REGISTRY
ED Entered STN: 27 Jul 2000
CN 5H-Imidazo[2,1-c][1,4]benzodiazepine, 2-(2-bromophenyl)-10-[[1-[(4-cyano-3-methoxyphenyl)methyl]-1H-imidazol-5-yl]acetyl]-6-fluoro-10,11-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BIM 2001
MF C31 H24 Br F N6 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 67.59 | 797.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | 0.00 | -12.00

FILE 'CAPLUS' ENTERED AT 11:08:48 ON 04 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 3 Dec 2006 (20061203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l42
L43 6 L42

=> d l43 1-6 ti abs bib

L43 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors
GI



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl,

heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps. Pharmaceutical composition comprising the compound I and methods of treating cancer and other diseases are disclosed.

AN 2006:759518 CAPLUS <<LOGINID::20061204>>

DN 145:188920

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe De Conseils De Recherches Et D'Applications Scientifiques, Sas, Fr.

SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 224,428, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7084135	B1	20060801	US 2001-868356	20010810
	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2006142275	A1	20060629	US 2006-353518	20060214
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	B2	19981231		
	WO 1999-US31302	W	19991230		
	EP 1999-968984	A3	19991230		
	US 2001-868356	A1	20010810		

OS MARPAT 145:188920

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

GI



I

AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 CAPLUS <<LOGINID::20061204>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500421	T2	20060105	JP 2004-539385	20030929
	US 2006166907	A1	20060727	US 2005-529431	20050325
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		

OS MARPAT 140:315043

L43 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the

mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 μM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 μM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN 2003:28618 CAPLUS <<LOGINID::20061204>>

DN 139:46523

TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor

AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jlidi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre

CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.

SO Biochemical Pharmacology (2003), 65(3), 423-433
CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns a product comprising at least mikanolide (I), dihydromikanolide or an analog, e.g., II [R1 = H, SR4, NR4R5; R2 = SR6, NR6R7; R3 = OH, O-acyl, O-silyl, O-carbamyl; R4, R6 = alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R5, R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R4R5 = 5- to 7-membered N-containing ring] and III, or their pharmaceutically acceptable salts, combined with at least one other anticancer agent for simultaneous, sep. or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analog thereof is combined with enzymic inhibitors such as G heterotrimeric protein inhibitors, IV [X = R22; Y = R18; XY = 6-membered ring, CHR18CHR19; R11 = H, lower alkyl, alkylthio; R12, R13 = H, lower alkyl; R14 = O, H2; R5 = H, lower alkyl, (cycloalkyl)alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R16, R17 = H, CONHCHR13CO2R14, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18R19 = aryl or heterocycly ring; R20, R21 = H, aryl, heterocyclyl, alkyl, arylalkyl, heterocyclylalkyl; R22 = NR9, S, O; R23 = ; R24 = H, lower alkyl], V (R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl;

R18R19 = aryl or heterocycly ring) or VI (R22 = NR9, S, O), or alkylating agents such as cis-platin. Thus, VII was prepared from mikanolide. VII was tested for cell proliferation inhibition activity [only 34% of cells lived when combined with VIII·HCl (vs. human colon cancer HT-29 cells)].

AN 2002:927175 CAPLUS <<LOGINID::20061204>>
DN 138:14131
TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire; Coulomb, Helene; Lavergne, Olivier; Lanco, Christophe; Teng, Beng-Poon
PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096348	A2	20021205	WO 2002-FR1800	20020529
	WO 2002096348	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2825278	A1	20021206	FR 2001-7104	20010530
	CA 2448528	AA	20021205	CA 2002-2448528	20020529
	EP 1438039	A2	20040721	EP 2002-738284	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004533456	T2	20041104	JP 2002-592861	20020529
	CN 1691941	A	20051102	CN 2002-812592	20020529
	US 2004138245	A1	20040715	US 2003-478387	20031211
PRAI	FR 2001-7104	A	20010530		
	WO 2002-FR1800	W	20020529		

OS MARPAT 138:14131

L43 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
AB The invention provides a product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent, in particular a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous, sep., or prolonged therapeutic use in cancer treatment.
AN 2001:359845 CAPLUS <<LOGINID::20061204>>
DN 134:361346
TI Product inhibiting heterotrimeric G protein signal transduction combined with another anticancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas; Morgan, Barry
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2001034203	A1	20010517	WO 2000-FR3098	20001108
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2800616	A1	20010511	FR 1999-14037	19991109
	FR 2800616	B1	20020118		
	FR 2803524	A1	20010713	FR 2000-104	20000106
	FR 2803524	B1	20020419		
	CA 2390317	AA	20010517	CA 2000-2390317	20001108
	EP 1233787	A1	20020828	EP 2000-976116	20001108
	EP 1233787	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200203241	A2	20030228	HU 2002-3241	20001108
	JP 2003513940	T2	20030415	JP 2001-536200	20001108
	EP 1430934	A1	20040623	EP 2004-75491	20001108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 284224	E	20041215	AT 2000-976116	20001108
	PT 1233787	T	20050429	PT 2000-976116	20001108
	ES 2234692	T3	20050701	ES 2000-976116	20001108
	US 7034024	B1	20060425	US 2002-129569	20020621
	US 2006074078	A1	20060406	US 2005-272304	20051110
PRAI	FR 1999-14037	A	19991109		
	FR 2000-104	A	20000106		
	EP 2000-976116	A3	20001108		
	WO 2000-FR3098	W	20001108		
	US 2002-129569	A3	20020621		

OS MARPAT 134:361346

RE.CNT 1. THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.

GI



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl,

cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

AN 2000:457071 CAPLUS <<LOGINID::20061204>>

DN 133:89553

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.

IN Gordon, Thomas B.; Morgan, Barry A.

PA Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.

SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2356756	AA	20000706	CA 1999-2356756	19991230
	EP 1140942	A2	20011010	EP 1999-968984	19991230
	EP 1140942	B1	20040310		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 200104708	A2	20020429	HU 2001-4708	19991230
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 261447	E	20040315	AT 1999-968984	19991230
	PT 1140942	T	20040531	PT 1999-968984	19991230
	ES 2215420	T3	20041001	ES 1999-968984	19991230
	RU 2241712	C2	20041210	RU 2001-121317	19991230
	NO 2001003281	A	20010829	NO 2001-3281	20010629
	NO 321057	B1	20060306		
	US 7084135	B1	20060801	US 2001-868356	20010810
	US 2006142275	A1	20060629	US 2006-353518	20060214
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	A1	19981231		
	EP 1999-968984	A3	19991230		
	WO 1999-US31302	W	19991230		
	US 2001-868356	A1	20010810		

OS MARPAT 133:89553

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.90	814.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE -4.50 -16.50

FILE 'USPATFULL' ENTERED AT 11:09:36 ON 04 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Nov 2006 (20061130/PD)
FILE LAST UPDATED: 30 Nov 2006 (20061130/ED)
HIGHEST GRANTED PATENT NUMBER: US7143445
HIGHEST APPLICATION PUBLICATION NUMBER: US2006272066
CA INDEXING IS CURRENT THROUGH 28 Nov 2006 (20061128/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Nov 2006 (20061130/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

=> s l42
L44 6 L42

=> d l44 1-6 ti abs bib

L44 ANSWER 1 OF 6 USPATFULL on STN
TI Prenyl transferase inhibitors
AB A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by formula (I): wherein X is (CHR.sup.11).sub.n3(CH.sub.2).sub.n4Z(CH.sub.2).sub.n5 where Z is O, N(R.sup.12), S, or a bond; Y is CO, CH.sub.2, CS, or a bond; R.sup.1 is A, B, C, D, E, F, G, H, I, J or N(R.sup.24R.sup.25); and the remaining substituents are as defined in the disclosure

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2006:198534 USPATFULL <<LOGINID::20061204>>
TI Prenyl transferase inhibitors
IN Gordon, Thomas D., Medway, MA, UNITED STATES
Morgan, Barry A., Franklin, MA, UNITED STATES
PA Societe de Conseils de Recherches et d'Applications Scientifiques, SAS, Paris, FRANCE (non-U.S. corporation)
PI US 7084135 B1 20060801
WO 2000039130 20000706
AI US 1999-868356 19991230 (9)
WO 1999-US31302 19991230
20010810 PCT 371 date
RLI Continuation-in-part of Ser. No. US 1998-224428, filed on 31 Dec 1998, ABANDONED
PRAI US 1998-114301P 19981231 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Fish & Richardson, Morrill, Brian R., Feeney, Alan F.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 2 OF 6 USPATFULL on STN
TI Composition for the treatment of nasopharyngeal carcinoma and method of use thereof
AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one

AN 2006:101425 USPATFULL <<LOGINID::20061204>>
TI Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
IN Prevost, Gregoire, Antony, FRANCE
Lonchampt, Marie-Odile, Chevilly-Larue, FRANCE
Gordon, Thomas, Medway, MA, UNITED STATES
Morgan, Barry, Franklin, MA, UNITED STATES
PA Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), FRANCE (non-U.S. corporation)
PI US 7034024 B1 20060425
WO 2001034203 20010517
AI US 2000-129569 20001108 (10)
WO 2000-FR3098 20001108
20020621 PCT 371 date
PRAI FR 1999-14037 19991109
FR 2000-104 20000106
DT Utility
FS GRANTED
EXNAM Primary Examiner: Hartley, Michael
LREP Muserlian, Charles A.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 5 OF 6 USPATFULL on STN
TI Product comprising a transduction inhibitor of heterotrimeric G protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
AB A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered simultaneously, separately or spread over a period of time and a pharmaceutical carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2006:87076 USPATFULL <<LOGINID::20061204>>
TI Product comprising a transduction inhibitor of heterotrimeric G protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
IN Prevost, Gregoire, Antony, FRANCE
Lonchampt, Marie-Odile, Chevilly-Larue, FRANCE
Gordon, Thomas, Medway, MA, UNITED STATES
Morgan, Barry, Franklin, MA, UNITED STATES
PA S.C.R.A.S. (non-U.S. corporation)
PI US 2006074078 A1 20060406
AI US 2005-272304 A1 20051110 (11)
RLI Division of Ser. No. US 2002-129569, filed on 21 Jun 2002, PENDING A 371 of International Ser. No. WO 2000-FR3098, filed on 8 Nov 2000
PRAI FR 1999-14037 19991109
FR 2000-104 20000106
DT Utility
FS APPLICATION
LREP Charles A. Muserlian, c/o Hedman and Costigan, 1185 Avenue of the Americas, New York, NY, 10036, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 6 OF 6 USPATFULL on STN

TI Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment

AB The invention concerns a product comprising at least mikanolide, dihydromikanolide or an analogue thereof combined with at least another anti-cancer agent for simultaneous, separate or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analogue thereof is combined with enzymatic inhibitors such as G heterotrimeric protein inhibitors or alkylating agents such as cis-platinum.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:179075 USPATFULL <<LOGINID::20061204>>

TI Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment

IN Prevost, Gregoire, Antony, FRANCE
Coulomb, Helene, Igny, FRANCE
Lavergne, Olivier, Palaiseau, FRANCE
Lanco, Christophe, Dourdan, FRANCE
Teng, Beng Poon, Gif-Sur-Yvette, FRANCE

PI US 2004138245 A1 20040715
AI US 2003-478387 A1 20031211 (10)
WO 2002-FR1800 20020529
PRAI FR 2001-7104 20010530
DT Utility
FS APPLICATION
LREP Muserlian, Lucas and Mercanti, 475 Park Avenue South, New York, NY, 10016
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.